Saturday, June 18, 2022 7:59:58 PM
An adjunct use of Ifenprodil with chemo for SCLC and cancer tumors may also be 'chased'. AGN licensed the IP.
One trick pony? Speculative investment and always has been, IMO.
The endpoints for the CC/IPF study will at least enable something CC. Maybe in Australia as AGN/NASH have THAT door as a solid backstay.
Most of us have been here through a lot chasing Breath and COVID. We know the past. There were obvious chances and risks.
I am speculating on the possible positive future.
These are ALL possibly big deals, IMO. A sustainable pipeline?
The current cards could be played quick as Shell implies some might. (imo). Long ago I posted to push the BTH run with small buys ( at least) to enable a BLO type run.
With some Positive Results and thoughtful actions AGN may move quick AND sustainably. .. (insert Sly + Family Stone @ Woodstock).
...GLTA...
...
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM